Aspire Biopharma Files Amended 2025 Annual Report

Ticker: ASBP · Form: 10-K/A · Filed: Apr 8, 2026 · CIK: 0001847345

Sentiment: neutral

Topics: amendment, annual-report, pharmaceuticals

TL;DR

Aspire Biopharma amended its 2025 10-K. Check financials.

AI Summary

Aspire Biopharma Holdings, Inc. filed an amended 10-K report on April 8, 2026, for the fiscal year ending December 31, 2025. The filing includes various exhibits such as financial statements and certifications. The company's principal business is in Pharmaceutical Preparations.

Why It Matters

This amended filing provides updated financial and operational details for Aspire Biopharma Holdings, Inc., crucial for investors and stakeholders to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — This is a routine amended filing of an annual report, not indicating new or elevated risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 10-K/A filing?

This 10-K/A filing is an amendment to the annual report for Aspire Biopharma Holdings, Inc. for the period ending December 31, 2025.

When was this amended filing accepted by the SEC?

The amended 10-K/A filing was accepted by the SEC on April 8, 2026.

What is Aspire Biopharma Holdings, Inc.'s SIC code?

Aspire Biopharma Holdings, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.

What is the CIK number for Aspire Biopharma Holdings, Inc.?

The CIK number for Aspire Biopharma Holdings, Inc. is 0001847345.

Where is Aspire Biopharma Holdings, Inc. located?

Aspire Biopharma Holdings, Inc. has its mailing and business address at 23150 FASHION DRIVE, SUITE 232, ESTERO FL 33928.

Filing Details

This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 8, 2026 regarding Aspire Biopharma Holdings, Inc. (ASBP).

View full filing on EDGAR

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on Read The Filing